Physician profile
Robert Stoke Daly
NPI 1255311981
$54,340.98
in general payments reported to CMS, 2019-2025
50 companies · $2,322 in 2025
The $2,322 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,960 · 2020: $4,229 · 2021: $15K · 2022: $12K · 2023: $16K · 2024: $3,371 · 2025: $2,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $7,023 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,300.00 |
| Food and Beverage | $7,022.84 |
| Education | $158.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $42,658.80 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,111.36 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,184.68 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $769.55 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $739.84 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Genzyme Corporation | $670.59 | 2020-2025 | |
| Pfizer INC. | $630.91 | 2019-2025 | |
| Insmed, INC. | $513.81 | 2019-2025 | Arikayce, Brinsupri |
| Jazz Pharmaceuticals INC. | $385.70 | 2020-2025 | |
| Amgen INC. | $354.00 | 2022-2025 | Tezspire |
| Harmony Biosciences LLC | $330.63 | 2024-2025 | |
| Mylan Specialty L.P. | $292.91 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $292.23 | 2020-2025 | Glassia |
| Electromed, INC. | $285.54 | 2021-2025 | Smartvest |
| Novartis Pharmaceuticals Corporation | $272.91 | 2019-2023 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $212.93 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| United Therapeutics Corporation | $191.99 | 2021-2025 | Tyvaso, Tyvaso |
| Csl Behring | $188.93 | 2019-2025 | Hizentra |
| Actelion Pharmaceuticals US, INC. | $172.41 | 2023-2025 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $158.83 | 2019-2024 | Eliquis |
| Paratek Pharmaceuticals, INC. | $158.66 | 2019-2024 | Nuzyra |
| Gilead Sciences, INC. | $154.97 | 2020-2021 | |
| Philips North America LLC | $146.52 | 2019-2025 | Vest Therapy Und |
| Merck Sharp & Dohme LLC | $141.89 | 2020-2025 | Zerbaxa, Recarbrio, Dificid |
| Janssen Pharmaceuticals, INC | $121.34 | 2020-2024 | Xarelto |
| Shionogi INC | $119.72 | 2023-2025 | Fetroja |
| Genentech USA, INC. | $117.61 | 2019-2023 | Xolair |
| Sanofi-Aventis U.S. LLC | $117.27 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $71.73 | 2020-2021 | |
| Novo Nordisk INC | $65.04 | 2019-2025 | Wegovy, Saxenda |
| Arbor Pharmaceuticals, INC. | $62.55 | 2021 | |
| Advanced Respiratory, INC | $57.60 | 2020 | |
| Shire North American Group INC | $53.67 | 2019 | |
| Inspire Medical Systems, INC. | $52.06 | 2023-2024 | Inspire |
| Pulmonx Corporation | $48.72 | 2023-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Octapharma USA, INC. | $46.66 | 2024-2025 | Cutaquig |
| Axsome Therapeutics, INC. | $41.02 | 2023 | Sunosi |
| Pharming Healthcare, INC. | $39.85 | 2023 | Ruconest |
| Astellas Pharma US INC | $35.62 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $34.67 | 2025 | Lumryz |
| Hospira, INC. | $33.98 | 2024-2025 | |
| Vifor Pharma, INC. | $32.17 | 2025 | Zemaira |
| Mayne Pharma Commercial LLC | $31.36 | 2019 | |
| Masimo Corporation | $31.02 | 2021 | |
| Abbvie INC. | $20.03 | 2021 | |
| Nabriva Therapeutics, Plc | $18.97 | 2021 | |
| Azurity Pharmaceuticals, INC. | $17.90 | 2024 | Horizant |
| Verona Pharma, INC. | $17.56 | 2025 | Ohtuvayre |
| Sunovion Pharmaceuticals INC. | $17.19 | 2019 | |
| Horizon Therapeutics Plc | $15.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Daly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.